Munk-Olsen, T
Current Regulatory Status Overview FDA Classification In 2023, the FDA placed BPC-157 in Category 2 of substances presenting significant safety risks, explicitly prohibiting its use in compounded medications
The cartilage finding is notable because it suggests the peptide acts through pathways relevant to connective tissue repair, not only lipolysis
CD36/fatty acid translocase, an inflammatory mediator, is involved in hyperlipidemia-induced exacerbation in ischemic brain injury
Known for its profound regenerative potential, BPC supports tissue healing far beyond the gutbenefiting tendons, ligaments, vasculature, the nervous system, and more.* Delivered in our proprietary liposomal format for enhanced and rapid uptake, this formula helps drive healing, supports cellular repair and protection, and helps modulate systemic inflammation for optimal regenerative benefits.* Weve reimagined traditionally delivered BPC from a promising therapeutic molecule into a convenient, non-invasive, and highly bioavailable solution
